期刊文献+

节律化疗诱导肿瘤休眠的研究进展 被引量:4

Progression of metronomic chemotherapy on inducing tumor dormancy
下载PDF
导出
摘要 肿瘤休眠是恶性肿瘤复发转移的基础,各种微转移病灶及循环中的肿瘤细胞和肿瘤干细胞被认为是休眠状态的肿瘤细胞可能的存在形式。目前认为靶向治疗及内分泌治疗等手段可以诱导肿瘤细胞长期处于休眠状态,抑制肿瘤复发。节律化疗是以小剂量持续给药为特点的化疗方式,可以抑制肿瘤血管生成、恢复宿主抗肿瘤免疫,是一种作用于肿瘤微环境,诱导肿瘤休眠的治疗手段。但因其用药方式、剂量及疗效判定方式尚无统一认识,对肿瘤细胞生物学行为的影响尚未清楚,需要进一步体内、体外实验证实。 Dormancy is the main reason of tumor recurrence and metastasis. Circulating tumor cells, tumor stem cells and mi- cro-metastasis may be dormancy cells. Targeted therapy and endocrine therapy can induce tumor dormancy in a long interval, that may reduce tumor relapse. Low-dose and short interval are two characteristics of metronomic chemotherapy. It can suppress tumor angiogen- esis and induce antitumor immunity. That means it can induce tumor dormancy through tumor microconditions. But how to use low-dose chemotherapy and what the optimal doses and interval time are unknown. How it affect tumor cells' actions is not clear, that needs in- depth studies, including many investigations in vitro and in vivo.
作者 乔京京 辛彦
出处 《临床肿瘤学杂志》 CAS 2013年第8期750-754,共5页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(81071650,81050007) 教育部高等学校博士学科点专项科研基金资助项目(20092104110008) 辽宁省教育厅高等学校科研项目计划(LS2010175) 辽宁省科学技术计划项目(2011404013-3)
关键词 节律化疗 肿瘤休眠 血管生成 Metronomic chemotherapy Tumor dormancy Angingenesis
  • 相关文献

参考文献38

  • 1Hanahan D, BergersG, Bergsland E. Less is more, regularly: met- ronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice [ J ]. J Clin Invest, 2000,105 ( 8 ) : 1045 - 1047.
  • 2Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis[ J] J Patho1,2010, 222( 1 ) : 1 - 15.
  • 3Brackstone M, Townson JL, Chambers AF, et al. Tumour dor- mancy in breast cancer: an update [ J ]. Breast Cancer Res, 2007, 9(3 ) :208.
  • 4Naumov GN, Folkman J, Straume O,et al. Tumor-vascular inter- actions and tumor dormancy [J ]. APMIS,2008,116 (7-8) : 569 -585.
  • 5Willis L, Alarc6n T, Ella G, et al. Breast cancer dormancy can he maintained by small numbers of micrometastases [ J ]. Cancer Res, 2010,70(11) :4310 -4317.
  • 6Uhra JW, Pantel K. Controversies in clinical cancer dormancy [J]. PNAS, 2011, 108(30) :12396 - 12400.
  • 7Xu Y, Li Q, Li XY, et al. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis [ J]. J Exp Clin Cancer Res, 2012, 31(1): 16.
  • 8Yang L, Ping YF, Yu X, et al. Gastric cancer stem-like cells possess higiler capability of invasion and metastasis in association with a mesenchymal transition phenotype [ J 1. Cancer Letters, 2011, 310(1) :46 -52.
  • 9Norkin M, Uberti JP, Schiffer CA. Very late recurrences of leu- kemia: why does leukemia awake after many years of dormancy? [J. Leuk Res, 2011,35(2):139-144.
  • 10Monteiro J, Fodde R. Cancer sternness and metastasis: Therapeu- tic consequences and perspectives [ J ]. Eur J Cancer,2010,46(7) :1198 - 1203.

共引文献3

同被引文献53

  • 1詹文华.Borrmann4型胃癌的特点及其处理对策[J].消化肿瘤杂志(电子版),2012,4(3):142-146. 被引量:3
  • 2戴明,罗荣城.时间生物学在肿瘤学的研究进展[J].癌症进展,2007,5(4):338-345. 被引量:12
  • 3于世英,王杰军,王金万,石远凯,江志伟,李进,沈琳,沈铿,徐瑞华,秦叔逵,谢广茹.晚期癌症患者合并肠梗阻治疗的专家共识[J].中华肿瘤杂志,2007,29(8):637-640. 被引量:144
  • 4秦叔逵,吴一龙,季加孚.中国临床肿瘤学进展2012[M].北京:人民卫生出版社,2012:312-416.
  • 5Gravalos C, SMut A, Carlos Garcfa-Gir6n C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leuco- vorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer [ J ]. Clin Transl Oncol, 2012,14 ( 8 ) :606 - 612.
  • 6苏广彦,刘玉琴,任乐荣,刘险峰,顾蓓,董继红,高进.乳腺癌休眠动物模型的建立[J].中华病理学杂志,2007,36(11):760-763. 被引量:2
  • 7Klein CA. Framework models of tumor dormancy from patient-derived observations[J]. Curr Opin Genet Dev, 2010,21(1) :42-49.
  • 8White AC, Khuu JK, Dang CY, et al. Stem cell quiescence acts as a tumour suppressor in squamous tumours[J]. Na- ture Cell Biol,2014,16(1) :99-107.
  • 9Bragado P, Sosa MS, Keely P, et al. Microenvironments dictating tumor cell dormancy[J]. Recent Results Cancer Res, 2012,195 : 25-39.
  • 10Shiozawa Y, McGee S, Pienta MJ, et al. Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis [J]. J Cell Biochem, 2013,114 ( 1 ) : 2471-2478.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部